On November 19, 2021, Merck, announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc., at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. As of the tender offer expiration on November 19, 2021, 38,752,614 shares of common stock of the Company were validly tendered and not withdrawn from the tender offer, representing approximately 63.3% of the total number of the Company?s outstanding shares.